{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000011","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.144889+00:00","generated_at":"2026-06-06T14:28:40.034345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BSX Q4 sales $3.73B (+14.9% reported), adj EPS $0.55; FY2024 adj EPS guidance $2.23-$2.27","bullets":["Q4 net sales $3.725B (+14.9% reported); GAAP EPS $0.34, adj EPS $0.55 beat guidance ranges.","FY2023 net sales $14.240B (+12.3% reported); GAAP EPS $1.07; adj EPS $2.05 versus $1.71 prior year.","FY2024 guidance: reported sales growth 8.5-9.5%; GAAP EPS $1.38-$1.42; adj EPS $2.23-$2.27.","FDA approved FARAPULSE PFA System for paroxysmal atrial fibrillation; enrollment in AVANT GUARD trial commenced.","Agreed to acquire Axonics (AXNX) for urinary/bowel dysfunction treatment; Relievant Medsystems acquisition completed."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000011","json":"https://secwatch.observer/filing/0000885725-24-000011.json","markdown":"https://secwatch.observer/filing/0000885725-24-000011.md","text":"https://secwatch.observer/filing/0000885725-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/0000885725-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/bsx-20240131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:28:40.034345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"341fb6528774221a11b6fcfffcd86ccb2f0ae0ca","claim":"BOSTON SCIENTIFIC CORP reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/0000885725-24-000011-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}